Recent advances in PI3K/PKB/mTOR inhibitors as new anticancer agents

MA Occhiuzzi, G Lico, G Ioele, M De Luca… - European Journal of …, 2023 - Elsevier
The biochemical role of the PI3K/PKB/mTOR signalling pathway in cell-cycle regulation is
now well known. During the onset and development of different forms of cancer it becomes …

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

L Yu, J Wei, P Liu - Seminars in cancer biology, 2022 - Elsevier
Cancer is the second leading cause of human death globally. PI3K/Akt/mTOR signaling is
one of the most frequently dysregulated signaling pathways observed in cancer patients that …

Recent advances in dual PI3K/mTOR inhibitors for tumour treatment

X Wu, Y Xu, Q Liang, X Yang, J Huang… - Frontiers in …, 2022 - frontiersin.org
The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat
various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes …

How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer

SM Afify, AKK Oo, G Hassan, A Seno… - Expert Review of …, 2021 - Taylor & Francis
ABSTRACT Introduction: The phosphatidylinositol 3-kinase/protein kinase-B/mammalian
target of rapamycin (PI3K/AKT/mTOR) pathway is a fundamental regulator of cell …

PI3 kinase inhibitors in the clinic: an update

JE Kurtz, I Ray-Coquard - Anticancer Research, 2012 - ar.iiarjournals.org
The phosphoinositide-3 kinase/protein kinase-B/mammalian target of rapamycin
(PI3K/AKT/mTOR) pathway has been identified as a key signaling pathway for important …

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

AS Alzahrani - Seminars in cancer biology, 2019 - Elsevier
Abstract Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR)
signaling pathway is one of the major cellular signaling pathways that plays an important …

PI3K and mTOR signaling pathways in cancer: new data on targeted therapies

L Willems, J Tamburini, N Chapuis, C Lacombe… - Current oncology …, 2012 - Springer
The mammalian target of rapamycin (mTOR) and the phosphoinositide 3-kinase (PI3K)
signaling pathways are commonly deregulated in cancers and promote cellular growth …

Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors

T Saurat, F Buron, N Rodrigues… - Journal of medicinal …, 2014 - ACS Publications
The design, synthesis, and screening of dual PI3K/mTOR inhibitors that gave nanomolar
enzymatic and cellular activities on both targets with an acceptable kinase selectivity profile …

Targeting PI3K/Akt/mTOR signaling in cancer

C Porta, C Paglino, A Mosca - Frontiers in oncology, 2014 - frontiersin.org
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress

P Wu, YZ Hu - Current medicinal chemistry, 2010 - ingentaconnect.com
The phosphoinositide 3-kinase (PI3K)/serine-theronine protein kinase Akt (also known as
protein kinase B (PKB))/mammalian target of rapamycin (mTOR) pathway is a vital …